DDInter1045 DDInter1376
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levamlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Levamlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tyropanoic acid
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levamlodipine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Levamlodipine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levamlodipine may lead to a major life threatening interaction when taken with Enzalutamide
Levamlodipine may lead to a major life threatening interaction when taken with Apalutamide